Search

Your search keyword '"Palmas, Angelo D."' showing total 20 results
Start Over Author "Palmas, Angelo D."
20 results on '"Palmas, Angelo D."'

1. Predictors of unsustained measurable residual disease negativity in patients with multiple myeloma

Author

D’Agostino, Mattia, primary, Bertuglia, Giuseppe, additional, Rota-Scalabrini, Delia, additional, Belotti, Angelo, additional, Morè, Sonia, additional, Corradini, Paolo, additional, Oliva, Stefania, additional, Ledda, Antonio, additional, Grasso, Mariella, additional, Pavone, Vincenzo, additional, Ronconi, Sonia, additional, Vincelli, Iolanda Donatella, additional, Ballanti, Stelvio, additional, Velluti, Cristina, additional, Cellini, Claudia, additional, Gozzetti, Alessandro, additional, Palmas, Angelo D., additional, Gamberi, Barbara, additional, Mancuso, Katia, additional, Paris, Laura, additional, Zambello, Renato, additional, Petrucci, Maria Teresa, additional, Bruno, Benedetto, additional, Musto, Pellegrino, additional, and Gay, Francesca, additional

Published
2024
Full Text
View/download PDF

2. Acute Myeloid Leukemia (AML) Risk Stratification Using the European Leukemianet 2022 Classification in a Real-Life Cohort of Patients from Sardinia, Italy

Author

Piras, Giovanna, primary, Uras, Antonella, additional, Cucca, Antonella, additional, Monne, Maria, additional, Costa, Alessandro, additional, Chiriu, Sabrina, additional, Longu, Francesco, additional, Murineddu, Marco, additional, Arru, Luigi Benedetto, additional, Bianchi, Alessandro, additional, Calvisi, Anna, additional, Di Francesco, Alessandra, additional, Murgia, Alessandro, additional, Cambosu, Francesca, additional, Flagiello, Mauro P, additional, Isoni, Maria Antonia, additional, Caocci, Giovanni, additional, Fozza, Claudio, additional, and Palmas, Angelo D., additional

Published
2022
Full Text
View/download PDF

5. Impact of Minimal Residual Disease (MRD) By Multiparameter Flow Cytometry (MFC) and Next-Generation Sequencing (NGS) on Outcome: Results of Newly Diagnosed Transplant-Eligible Multiple Myeloma (MM) Patients Enrolled in the Forte Trial

Author

Oliva, Stefania, primary, Genuardi, Elisa, additional, Petrucci, Maria Teresa, additional, D'Agostino, Mattia, additional, Auclair, Daniel, additional, Spadano, Antonio, additional, Jacob, Allison P., additional, Cea, Michele, additional, De Rosa, Luca, additional, Gozzetti, Alessandro, additional, Ruggeri, Marina, additional, Capra, Andrea, additional, Gilestro, Milena, additional, Pescosta, Norbert, additional, Palmas, Angelo D., additional, Siniscalchi, Agostina, additional, Kirsch, Ilan R., additional, Corradini, Paolo, additional, Musto, Pellegrino, additional, Boccadoro, Mario, additional, Zamagni, Elena, additional, and Gay, Francesca, additional

Published
2020
Full Text
View/download PDF

6. Minimal Residual Disease Evaluation By Multiparameter Flow Cytometry and Next Generation Sequencing in the Forte Trial for Newly Diagnosed Multiple Myeloma Patients

Author

Oliva, Stefania, primary, Genuardi, Elisa, additional, Belotti, Angelo, additional, Frascione, Pio Manlio Mirko, additional, Galli, Monica, additional, Capra, Andrea, additional, Offidani, Massimo, additional, Vozella, Federico, additional, Zambello, Renato, additional, Auclair, Daniel, additional, Siniscalchi, Agostina, additional, Yesil, Jennifer, additional, Annibali, Ombretta, additional, Kirsch, Ilan M., additional, Caltagirone, Simona, additional, Jacob, Allison P., additional, Ballanti, Stelvio, additional, Palmas, Angelo D., additional, Ledda, Antonio, additional, Corradini, Paolo, additional, Omedé, Paola, additional, Cavo, Michele, additional, Musto, Pellegrino, additional, Boccadoro, Mario, additional, and Gay, Francesca, additional

Published
2019
Full Text
View/download PDF

7. Updated efficacy data and MRD analysis according to risk status in newly diagnosed myeloma patients treated with carfilzomib + lenalidomide or cyclophosphamide (FORTE trial).

Author

Gay, Francesca Maria, primary, Foà, Robin, additional, Musto, Pellegrino, additional, Cerrato, Chiara, additional, Gamberi, Barbara, additional, Zamagni, Elena, additional, Palmas, Angelo D., additional, Spadano, Antonio, additional, Omedè, Paola, additional, Caravita, Tommaso, additional, Giuliani, Nicola, additional, Ballanti, Stelvio, additional, Patriarca, Francesca, additional, Troia, Rossella, additional, Gentile, Massimo, additional, Desabbata, Giovanni, additional, Canepa, Letizia, additional, Palumbo, Antonio, additional, Cavo, Michele, additional, and Boccadoro, Mario, additional

Published
2018
Full Text
View/download PDF

8. Carfilzomib-lenalidomide-dexamethasone (KRd) vs carfilzomib-cyclophosphamide-dexamethasone (KCd) induction: Planned interim analysis of the randomized FORTE trial in newly diagnosed multiple myeloma (NDMM).

Author

Gay, Francesca Maria, primary, Rota Scalabrini, Delia, additional, Belotti, Angelo, additional, Offidani, Massimo, additional, Petrucci, Maria Teresa, additional, Esma, Fabrizio, additional, Palmas, Angelo D., additional, Caravita, Tommaso, additional, Grasso, Mariella, additional, Aquino, Sara, additional, Gamberi, Barbara, additional, Zambello, Renato, additional, Ledda, Antonio, additional, Montefusco, Vittorio, additional, Omedè, Paola, additional, Galli, Monica, additional, Cavo, Michele, additional, Palumbo, Antonio, additional, Musto, Pellegrino, additional, and Boccadoro, Mario, additional

Published
2017
Full Text
View/download PDF

9. Upfront Single Versus Double Autologous Stem Cell Transplantation for Newly Diagnosed Multiple Myeloma: An Intergroup, Multicenter, Phase III Study of the European Myeloma Network (EMN02/HO95 MM Trial)

Author

Cavo, Michele, primary, Petrucci, Maria Teresa, additional, Di Raimondo, Francesco, additional, Zamagni, Elena, additional, Gamberi, Barbara, additional, Crippa, Claudia, additional, Marzocchi, Giulia, additional, Grasso, Mariella, additional, Ballanti, Stelvio, additional, Vincelli, Donatella Iolanda, additional, Tacchetti, Paola, additional, Offidani, Massimo, additional, Semenzato, Gianpietro, additional, Liberati, Anna Marina, additional, Pascarella, Anna, additional, Benevolo, Giulia, additional, Troia, Rossella, additional, Palmas, Angelo D., additional, Cantore, Nicola, additional, Rizzi, Rita, additional, Morabito, Fortunato, additional, Boccadoro, Mario, additional, and Sonneveld, Pieter, additional

Published
2016
Full Text
View/download PDF

10. Isatuximab-Based Regimens As Salvage Therapy for Patients with Multiple Myeloma: Sardinian, Multicenter, Retrospective Clinical Practice Experience with 27 Cases Outside of Controlled Clinical Trials

Author

Derudas, Daniele, Podda, Luigi, Palmas, Angelo D., Floris, Rita, Liguori, Annamaria, Depau, Cristina, Bianchi, Alessandro, Fozza, Claudio, and La Nasa, Giorgio

Abstract

Introduction:Isatuximab (Isa), a humanized monoclonal antibody directed against the surface antigen CD38, has been available in Italy since October 2021 for the treatment of relapsed or refractory Multiple Myeloma (RRMM) in combination with Pomalidomide (P) and Dexamethasone (d) (IsaPd) after two lines of therapy with lenalidomide and a proteosome inhibitor, and from April 2022 in combination with carfilzomib (K) after one line of treatment. Patients eligible for these therapies must not be refractory to Daratumumab. Here, we report preliminary efficacy and safety data for Isatuximab in a Sardinian study of RRMM patients treated with IsaPd and IsaKda as salvage therapy outside of controlled clinical trials. The primary objective of this study was to evaluate the toxicity profile and quality of response to Isatuximab-based regimens administered as salvage therapy in a real-world setting.

Published
2023
Full Text
View/download PDF

11. Double Autologous Stem Cell Transplantation Significantly Prolongs Progression-Free Survival and Overall Survival in Comparison with Single Autotransplantation in Newly Diagnosed Multiple Myeloma: An Analysis of Phase 3 EMN02/HO95 Study

Author

Cavo, Michele, Gay, Francesca Maria, Patriarca, Francesca, Zamagni, Elena, Montefusco, Vittorio, Dozza, Luca, Galli, Monica, Bringhen, Sara, Testoni, Nicoletta, Grasso, Mariella, Ballanti, Stelvio, Tacchetti, Paola, Semenzato, Giampietro, Liberati, Anna Marina, Benevolo, Giulia, Spriano, Mauro, Di Bartolomeo, Paolo, Caravita di Toritto, Tommaso, Palmas, Angelo D., Cafro, Anna Maria, Morabito, Fortunato, Musto, Pellegrino, Rizzi, Rita, Palumbo, Antonio, and Sonneveld, Pieter

Published
2017
Full Text
View/download PDF

12. Virtual Karyotype Reconstruction By SNPs Array of Newly Diagnosed Multiple Myeloma (MM) Patients Enrolled in the EMN02 Clinical Trial

Author

Terragna, Carolina, primary, Dico, Angela Flores, additional, Martello, Marina, additional, Callea, Vincenzo, additional, Catania, Gioacchino, additional, Spadano, Tonino, additional, Caravita di Toritto, Tommaso, additional, Testoni, Nicoletta, additional, Waage, Anders, additional, Borsi, Enrica, additional, Palumbo, Antonio, additional, Zweegman, Sonja, additional, Cafro, Annamaria, additional, Palmas, Angelo D., additional, Volpe, Silvestro, additional, Prete, Marcella, additional, Vigna, Ernesto, additional, De Rosa, Luca, additional, Cellini, Claudia, additional, Sonneveld, Pieter, additional, and Cavo, Michele, additional

Published
2014
Full Text
View/download PDF

15. Predictors of unsustained measurable residual disease negativity in patients with multiple myeloma

Author

D’Agostino, Mattia, Bertuglia, Giuseppe, Rota-Scalabrini, Delia, Belotti, Angelo, Morè, Sonia, Corradini, Paolo, Oliva, Stefania, Ledda, Antonio, Grasso, Mariella, Pavone, Vincenzo, Ronconi, Sonia, Vincelli, Iolanda Donatella, Ballanti, Stelvio, Velluti, Cristina, Cellini, Claudia, Gozzetti, Alessandro, Palmas, Angelo D., Gamberi, Barbara, Mancuso, Katia, Paris, Laura, Zambello, Renato, Petrucci, Maria Teresa, Bruno, Benedetto, Musto, Pellegrino, and Gay, Francesca

Abstract

•Amp(1q), HRCA ≥2, high CTC levels, and a longer time to reach first MRD negativity are significant predictors of unsustained MRD negativity.•Maintenance treatment with carfilzomib-lenalidomide reduces the risk of unsustained MRD negativity vs lenalidomide alone.

Published
2023
Full Text
View/download PDF

16. Analysis of BCL11A gene Variants in Hematological Malignancies.

Author

Monne, Maria, primary, Piras, Giovanna, additional, Uras, Antonella, additional, Murineddu, Marco, additional, Palmas, Angelo D., additional, Pira, Giovanna, additional, Fancello, Maria Antonietta, additional, Latte, Gian Carlo, additional, Murgia, Alessandro, additional, Novelli, Angelo, additional, Deledda, Salvatore, additional, and Gabbas, Attilio, additional

Published
2009
Full Text
View/download PDF

20. Predictors of unsustained measurable residual disease negativity in patients with multiple myeloma.

Author

D'Agostino M, Bertuglia G, Rota-Scalabrini D, Belotti A, Morè S, Corradini P, Oliva S, Ledda A, Grasso M, Pavone V, Ronconi S, Vincelli ID, Ballanti S, Velluti C, Cellini C, Gozzetti A, Palmas AD, Gamberi B, Mancuso K, Paris L, Zambello R, Petrucci MT, Bruno B, Musto P, and Gay F

Subjects
Humans, Lenalidomide therapeutic use, Treatment Outcome, Neoplasm, Residual, Prognosis, Multiple Myeloma drug therapy
Abstract

Abstract: The prognostic impact of achieving and in particular maintaining measurable residual disease (MRD) negativity in multiple myeloma is now established; therefore, identifying among MRD-negative patients the ones at higher risk of losing MRD negativity is of importance. We analyzed predictors of unsustained MRD negativity in patients enrolled in the FORTE trial (NCT02203643). MRD was performed by multiparameter flow cytometry (sensitivity of 10-5) at premaintenance and every 6 months thereafter. The cumulative incidence (CI) of MRD resurgence and/or progression was analyzed in MRD-negative patients. A total of 306 of 474 (65%) MRD-negative patients were analyzed. After a median follow-up of 50.4 months from MRD negativity, 185 of 306 (60%) patients were still MRD negative and progression free, 118 (39%) lost their MRD-negative status, and 3 patients (1%) died without progression. Amp1q vs normal (4-year CI, 63% vs 34), ≥2 concomitant high-risk cytogenetic abnormalities vs 0 (4-year CI, 59% vs 33%), circulating tumor cells at baseline (high vs low at 4-year CI, 62% vs 32%), and time-to-reach MRD negativity postconsolidation vs preconsolidation (4-year CI, 46% vs 35%) were associated with a higher risk of unsustained MRD negativity in a multivariate Fine-Gray model. During the first 2 years of maintenance, patients receiving carfilzomib-lenalidomide vs lenalidomide alone had a lower risk of unsustained MRD negativity (4-year CI, 20% vs 33%)., (© 2024 American Society of Hematology. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.)

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results